These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38262735)

  • 21. Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine.
    De Gregorio D; Aguilar-Valles A; Preller KH; Heifets BD; Hibicke M; Mitchell J; Gobbi G
    J Neurosci; 2021 Feb; 41(5):891-900. PubMed ID: 33257322
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lifetime use of MDMA/ecstasy and psilocybin is associated with reduced odds of major depressive episodes.
    Jones GM; Nock MK
    J Psychopharmacol; 2022 Jan; 36(1):57-65. PubMed ID: 34983261
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ecstasy and drug consumption patterns: a Canadian rave population study.
    Gross SR; Barrett SP; Shestowsky JS; Pihl RO
    Can J Psychiatry; 2002 Aug; 47(6):546-51. PubMed ID: 12211882
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Psychedelics and Psychedelic-Assisted Psychotherapy.
    Reiff CM; Richman EE; Nemeroff CB; Carpenter LL; Widge AS; Rodriguez CI; Kalin NH; McDonald WM;
    Am J Psychiatry; 2020 May; 177(5):391-410. PubMed ID: 32098487
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Self-reported prevalence of dependence of MDMA compared to cocaine, mephedrone and ketamine among a sample of recreational poly-drug users.
    Uosukainen H; Tacke U; Winstock AR
    Int J Drug Policy; 2015 Jan; 26(1):78-83. PubMed ID: 25107829
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Can MDMA play a role in the treatment of substance abuse?
    Jerome L; Schuster S; Yazar-Klosinski BB
    Curr Drug Abuse Rev; 2013 Mar; 6(1):54-62. PubMed ID: 23627786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychedelic drugs-a new era in
psychiatry?
.
    Nutt D
    Dialogues Clin Neurosci; 2019; 21(2):139-147. PubMed ID: 31636488
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Club drug use among youths in treatment for substance abuse.
    Hopfer C; Mendelson B; Van Leeuwen JM; Kelly S; Hooks S
    Am J Addict; 2006; 15(1):94-9. PubMed ID: 16449098
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compassionate use of psychedelics.
    Greif A; Šurkala M
    Med Health Care Philos; 2020 Sep; 23(3):485-496. PubMed ID: 32468195
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Substance use during the COVID-19 pandemic: What is really happening?
    Mellos E; Paparrigopoulos T
    Psychiatriki; 2022 Mar; 33(1):17-20. PubMed ID: 35255473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Profiles of urine samples from participants at rave party in Taiwan: prevalence of ketamine and MDMA abuse.
    Lua AC; Lin HR; Tseng YT; Hu AR; Yeh PC
    Forensic Sci Int; 2003 Sep; 136(1-3):47-51. PubMed ID: 12969619
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths.
    Wu LT; Schlenger WE; Galvin DM
    Drug Alcohol Depend; 2006 Sep; 84(1):102-13. PubMed ID: 16483730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.
    Breeksema JJ; Kuin BW; Kamphuis J; van den Brink W; Vermetten E; Schoevers RA
    J Psychopharmacol; 2022 Oct; 36(10):1100-1117. PubMed ID: 36017784
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Why MDMA therapy for alcohol use disorder? And why now?
    Sessa B
    Neuropharmacology; 2018 Nov; 142():83-88. PubMed ID: 29126911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Psychedelics and quasi-psychedelics in the light of contemporary research: medical cannabis, MDMA, salvinorin A, ibogaine and ayahuasca].
    Szabó A; Kazai A; Frecska E; Brys Z
    Neuropsychopharmacol Hung; 2015 Sep; 17(3):120-8. PubMed ID: 26485742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of MDMA and other illicit drugs by young adult males in northern Spain. A five-year study.
    Bobes J; Sáiz PA; González MP; Bascarán MT; Bousoño M; Ricaurte GA; McCann UD
    Eur Addict Res; 2002 Jun; 8(3):147-54. PubMed ID: 12065965
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Psychedelic use is associated with reduced daily opioid use among people who use illicit drugs in a Canadian setting.
    Argento E; Socias ME; Hayashi K; Choi J; Mackay L; Christie D; Milloy MJ; DeBeck K
    Int J Drug Policy; 2022 Feb; 100():103518. PubMed ID: 34758431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identifying early intervention opportunities for illicit stimulant use: A cross-sectional study of factors associated with illicit stimulant use among young people accessing integrated youth services in British Columbia, Canada.
    Kreim S; Marchand K; Mallia E; Dubras R; McMaster WR; Tee K; Mathias S; Barbic S
    J Subst Use Addict Treat; 2023 Aug; 151():209076. PubMed ID: 37182544
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The emerging role of psilocybin and MDMA in the treatment of mental illness.
    Gill H; Gill B; Chen-Li D; El-Halabi S; Rodrigues NB; Cha DS; Lipsitz O; Lee Y; Rosenblat JD; Majeed A; Mansur RB; Nasri F; Ho R; McIntyre RS
    Expert Rev Neurother; 2020 Dec; 20(12):1263-1273. PubMed ID: 32954860
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cognitive functioning associated with acute and subacute effects of classic psychedelics and MDMA - a systematic review and meta-analysis.
    Basedow LA; Majić T; Hafiz NJ; Algharably EAE; Kreutz R; Riemer TG
    Sci Rep; 2024 Jun; 14(1):14782. PubMed ID: 38926480
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.